NEW YORK – ANP Technologies has received Emergency Use Authorization from the US Food and Drug Administration for its NIDS COVID-19 Antigen Home Test, according to the agency said on Thursday.
The lateral flow test is intended for non-prescription home use, and it qualitatively detects the nucleocapsid protein antigen from SARS-CoV-2. It can be used with anterior nasal swab samples and is authorized for use by people with symptoms of COVID-19 within the first five days of symptom onset when tested at least twice over three days, with at least 48 hours between tests. It is also authorized for use by people without symptoms or other reasons to suspect COVID-19 when tested at least three times over five days with at least 48 hours between tests, the FDA said in its authorization letter.
Newark, Delaware-based ANP Technologies previously received EUA in 2021 for its NIDS COVID-19 Antigen Rapid Test Kit, which uses the firm's Nano-Intelligent Detection System platform.